| 3 months after start | 6 months after start | 9 months after start | 12 months after start |
---|---|---|---|---|
N = 12 | N = 11 | N = 12 | N = 12 | |
FEV1% (SD) | (16 ±)65.7 | (18.3 ±)61.5 | (17.6 ±)62.6 | (15.8 ±)60.6 |
 Change from baseline | 5.7 | 0.7 | 2.6 | 0.6 |
 P-value | 0.009 | 0.861 | 0.34 | 0.921 |
FVC% (SD) | (18.6 ±)82.8 | (17.7 ±)80.9 | (18.2 ±)77.1 | (17.5 ±)78.2 |
 Change from baseline | 7.3 | 4.6 | 1.6 | 2.7 |
 P-value | 0.027 | 0.0371 | 0.0775 | 0.0626 |
FEF25-75% (SD) | (17 ±)34.5 | (17.2 ±)31.1 | (17.3 ±)32.6 | (19.9 ±)34 |
 Change from baseline | 4.3 | 0.5 | 2.5 | 3.9 |
 P-value | 0.001 | 0.764 | 0.181 | 0.672 |
CT Score (SD)a | - | - | - | (2.7 ±)12.5 |
 Change from baseline | - | - | - | -0.3 |
 P-value | - | - | - | 0.517 |